Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) saw a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 17,200 shares, a growth of 25.5% from the January 31st total of 13,700 shares. Currently, 0.5% of the company's shares are short sold. Based on an average daily volume of 33,700 shares, the days-to-cover ratio is presently 0.5 days.
Assembly Biosciences Stock Performance
ASMB traded down $0.31 during midday trading on Friday, reaching $11.12. 37,371 shares of the company were exchanged, compared to its average volume of 24,325. The company's fifty day moving average price is $14.06 and its 200 day moving average price is $15.47. Assembly Biosciences has a one year low of $10.89 and a one year high of $19.93.
Insider Activity
In other news, Director Michael Houghton bought 3,202 shares of the firm's stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average cost of $15.61 per share, with a total value of $49,983.22. Following the transaction, the director now directly owns 3,202 shares of the company's stock, valued at approximately $49,983.22. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.10% of the stock is owned by company insiders.
Institutional Trading of Assembly Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASMB. Gilead Sciences Inc. bought a new stake in Assembly Biosciences during the 4th quarter worth approximately $34,865,000. Peapod Lane Capital LLC bought a new stake in Assembly Biosciences during the 4th quarter worth approximately $994,000. B Group Inc. bought a new stake in Assembly Biosciences during the 4th quarter worth approximately $799,000. Monimus Capital Management LP bought a new stake in Assembly Biosciences during the 4th quarter worth approximately $664,000. Finally, Renaissance Technologies LLC increased its holdings in Assembly Biosciences by 44.3% during the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company's stock worth $1,495,000 after purchasing an additional 29,087 shares in the last quarter. 19.92% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "neutral" rating on shares of Assembly Biosciences in a research report on Friday, December 27th.
Read Our Latest Research Report on Assembly Biosciences
About Assembly Biosciences
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Read More
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
